Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $47.00 Consensus Target Price from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $47.00.

A number of brokerages have issued reports on COLL. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday. Barclays initiated coverage on shares of Collegium Pharmaceutical in a research note on Monday, December 8th. They set an “overweight” rating and a $58.00 price objective on the stock. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Zacks Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares of the company’s stock, valued at $4,991,038.21. This represents a 14.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director directly owned 52,629 shares in the company, valued at $2,475,141.87. This represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 51,250 shares of company stock valued at $2,235,352. Corporate insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in COLL. Amundi increased its stake in Collegium Pharmaceutical by 302.1% during the 1st quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company’s stock valued at $1,816,000 after buying an additional 47,024 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Collegium Pharmaceutical by 3.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company’s stock worth $7,389,000 after acquiring an additional 7,614 shares during the period. Fortis Capital Advisors LLC bought a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $408,000. Rhumbline Advisers boosted its holdings in shares of Collegium Pharmaceutical by 3.1% in the first quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company’s stock valued at $3,332,000 after acquiring an additional 3,400 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Collegium Pharmaceutical during the first quarter valued at approximately $2,674,000.

Collegium Pharmaceutical Price Performance

COLL opened at $48.88 on Wednesday. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $49.92. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of 30.36 and a beta of 0.61. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. The company has a fifty day simple moving average of $42.28 and a 200 day simple moving average of $36.62.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The company had revenue of $135.55 million during the quarter. Equities research analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.